Adaptive HIV pre-exposure prophylaxis adherence interventions for young South African women: Study protocol for a sequential multiple assignment randomized trial

Jennifer Velloza, Nicole Poovan, Nontokozo Ndlovu, Nomhle Khoza, Jennifer F Morton, Jeanne Omony, Edwin Mkwanazi, Cole Grabow, Deborah Donnell, Richard Munthali, Jared M Baeten, Sybil Hosek, Connie Celum, Sinead Delany-Moretlwe, Jennifer Velloza, Nicole Poovan, Nontokozo Ndlovu, Nomhle Khoza, Jennifer F Morton, Jeanne Omony, Edwin Mkwanazi, Cole Grabow, Deborah Donnell, Richard Munthali, Jared M Baeten, Sybil Hosek, Connie Celum, Sinead Delany-Moretlwe

Abstract

Introduction: Pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention strategy and is recommended for populations at risk of HIV, including adolescent girls and young women (AGYW) in HIV endemic settings. However, PrEP continuation and high adherence remain challenges to its impact. Existing PrEP adherence interventions can be time- and cost-intensive. Widescale PrEP delivery will require the identification of layered PrEP support strategies for AGYW with diverse prevention needs. We describe the design of a sequential multiple assignment randomized trial (SMART) to evaluate a PrEP adherence support model using scalable, stepped interventions in AGYW in South Africa.

Methods: "PrEP SMART" is a randomized trial in Johannesburg, South Africa, enrolling AGYW who are between 18 and 25 years of age, sexually active, newly initiating PrEP, and have regular access to a mobile phone. Participants are randomized 1:1 to standard-of-care PrEP counseling with either two-way SMS or WhatsApp group adherence support. Adherence is assessed at three months using tenofovir diphosphate (TFV-DP) levels from dried blood spots collected at month 2 to categorize participants as "responders" (TFV-DP ≥500 fmol/punch) or "non-responders" (TFV-DP <500 fmol/punch). AGYW defined as 'non-responders' undergo a secondary 1:1 randomization to either quarterly drug-level feedback counseling or monthly issue-focused counseling, in addition to their first-level intervention. The primary outcome is PrEP adherence at nine months (TFV-DP ≥700 fmol/punch). We will assess the effect of our two initial interventions on TFV-DP levels among responders, assess the effect of our intensified interventions on TFV-DP levels among non-responders, and identify the optimal sequence of adherence interventions through nine months.

Trial registration: ClinicalTrials.gov, NCT04038060. Registered on 30 July 2019.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Schedule of enrollment, interventions, and…
Fig 1. Schedule of enrollment, interventions, and assessments for PrEP SMART study.
ENR = enrollment; M1 = Month 1; CASI = computer assisted self-interview; STI = sexually transmitted infection; TFV-DP = tenofovir diphosphate; DBS = dried blood spots. 1Only participants who are “non-responders” to their primary intervention will be randomized at the Month 3 study visit. 2Drug concentration testing will occur at Month 2 for all participants to determine whether they are “non-responders” to the primary intervention; drug concentration testing will occur at Months 3 and 6 only for participants in the drug-level feedback counseling arm. TFV-DP levels will also be assessed among all participants at Month 9 for primary outcome assessment.
Fig 2. Flow diagram of study enrollment,…
Fig 2. Flow diagram of study enrollment, randomization, and intervention arms.
1A participant is considered a “non-responder” if they have Month 2 TFV-DP levels <500 fmol/punch or missed PrEP refills at the Month 1 and/or Month 2 study visits. Secondary randomization takes place at the Month 3 study visit.
Fig 3. Drug-level feedback counseling messages and…
Fig 3. Drug-level feedback counseling messages and corresponding TFV-DP thresholds.
“Sample month” refers to the month when the TFV-DP sample was collected. “Results month” refers to the month when the results were given to the participant (e.g., for blood samples drawn at the Month 2 visit, TFV-DP results were reported to participants during their Month 3 visit. For TFV-DP levels greater than or equal to 500 fmol/punch, participants were shown the green wifi signal as a visual representation of their drug levels and they were told the accompanying counseling message by the counselor. For TFV-DP levels between detectable (>16 fmol/punch) and 499 fmol/punch, participants were shown the yellow wifi signal and were told the accompanying counseling message. Finally, for TFV-DP levels below the limit of quantification, participants were shown the red wifi signal and were told the accompanying counseling message.

References

    1. Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet. 2019;394(10195):303–13. doi: 10.1016/S0140-6736(19)31288-7
    1. Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al.. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121–2132. doi: 10.1056/NEJMoa1506110
    1. UNAIDS. Trend in New Infections: Eastern, Southern, Western, Central Africa by Sex. [Internet]. 2018. [cited 2021 December 21]. Available from: .
    1. UNAIDS. UNAIDS Global HIV/AIDS Factsheet. [Internet]. 2017. [cited 2021 December 21]. Available from: .
    1. Haberer JE, Mugo N, Baeten JM, Pyra M, Bukusi E, Bekker LG. PrEP as a lifestyle and investment for adolescent girls and young women in Sub-Saharan Africa. J Int Assoc Provid AIDS Care. 2019;18:2325958219831011. doi: 10.1177/2325958219831011
    1. Celum CL, Delany-Moretlwe S, McConnell M, van Rooyen H, Bekker LG, Kurth A, et al.. Rethinking HIV prevention to prepare for oral PrEP implementation for young African women. J Int AIDS Soc. 2015;18(4 Suppl 3):20227. doi: 10.7448/IAS.18.4.20227
    1. Baeten JM, Heffron R, Kidoguchi L, Mugo NR, Katabira E, Bukusi EA, et al.. Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV-1-serodiscordant couples: a prospective implementation study in Kenya and Uganda. PLoS Med. 2016;13(8):e1002099. doi: 10.1371/journal.pmed.1002099
    1. Heffron R, Ngure K, Odoyo J, Bulya N, Tindimwebwa E, Hong T, et al.. Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa. Gates Open Res. 2017;1(3).
    1. Bekker LG, Roux S, Sebastien E, Yola N, Amico KR, Hughes JP, et al.. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Lancet HIV. 2017;5(2):e68–e78. doi: 10.1016/S2352-3018(17)30156-X
    1. Grant RM, Mannheimer S, Hughes JP, Hirsch-Moverman Y, Loquere A, Chitwarakorn A, et al.. Daily and nondaily oral preexposure prophylaxis in men and transgender women who have sex with men: the Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. Clin Infect Dis. 2018;66(11):1712–1721. doi: 10.1093/cid/cix1086
    1. Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, et al.. An HIV preexposure prophylaxis demonstration project and safety study for young MSM. J Acquir Immune Defic Syndr. 2017;74(1):21–29. doi: 10.1097/QAI.0000000000001179
    1. Grinsztejn B, Hoagland B, Moreira RI, Kallas EG, Madruga JV, Goulart S, et al.. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. Lancet HIV. 2018;5(3):e136–45. doi: 10.1016/S2352-3018(18)30008-0
    1. Gill K, Dietrich J, Gray G, Pidwell T, Kayamba E, Bennie T, et al.. Pluspills: an open label, safety and feasibility study of oral pre-exposure prophylaxis (PrEP) in 15–19 year old adolescents in two sites in South Africa. Abstract #TUAC0207LB. 9th International AIDS Society Conference (IAS) on HIV Science; July 23–26, 2017; Paris, France.
    1. Amico KR, Wallace M, Bekker LG, Roux S, Atujuna M, Sebastian E, et al.. Experiences with HPTN 067/ADAPT study-provided open-label PrEP among women in Cape Town: facilitators and barriers within a mutuality framework. AIDS Behav. 2017;21(5):1361–1375. doi: 10.1007/s10461-016-1458-y
    1. World Health Organization‎. WHO implementation tool for pre-exposure prophylaxis (‎‎PrEP)‎‎ of HIV infection—Module 12: adolescents and young adults. World Health Organization. 2018; Accessed July 31, 2019. Available at: . License: CC BY-NC-SA 3.0 IGO.
    1. South African National AIDS Council (SANAC). National Strategic Plan 2017–2022; 2017. Accessed July 31, 2019. Available at: .
    1. UNAIDS. HIV Prevention among Adolescent Girls and Youth Women: Putting HIV Prevention among Adolescent Girls and Young Women on the Fast-Track and Engaging Men and Boys. UNAIDS; 2016. Accessed July 31, 2019. Available at: .
    1. South Africa: A snapshot of PrEP scale-up, registration and resources for South Africa. In: PrEP Watch. Accessed January 13, 2021. Available at: .
    1. Van Damme L, Corneli A, Ahmed K, Lombaard J, Kapiga S, Malahleha M, et al.. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–422. doi: 10.1056/NEJMoa1202614
    1. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al.. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–518. doi: 10.1056/NEJMoa1402269
    1. Stankevitz K, Grant H, Lloyd J, Gomez GB, Kripke K, Torjesen K, Ong K, Terris-Prestholt F. Oral preexposure prophylaxis continuation, measurement and reporting. AIDS. 2020;34(12):1801–1811. doi: 10.1097/QAD.0000000000002598
    1. Hosek S, Celum C, Wilson CM, Kapogiannis B, Delany-Moretlwe S, Bekker LG. Preventing HIV among adolescents with oral PrEP: observations and challenges in the United States and South Africa. J Int AIDS Soc. 2016;19(7 (Suppl 6)):21107. doi: 10.7448/IAS.19.7.21107
    1. Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye BJ, et al.. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. PLoS Med. 2021;18(6):e1003670. doi: 10.1371/journal.pmed.1003670
    1. Cabral A, M Baeten J, Ngure K, Velloza J, Odoyo J, Haberer JE, et al.. Intimate partner violence and self-reported pre-exposure prophylaxis interruptions among HIV-negative partners in HIV serodiscordant couples in Kenya and Uganda. J Acquir Immune Defic Syndr. 2018;77(2):154–159. doi: 10.1097/QAI.0000000000001574
    1. Velloza J, Heffron R, Amico KR, Rowhani-Rahbar A, Hughes JP, Li M, et al.. The effect of depression on adherence to HIV pre-exposure prophylaxis among high-risk South African women in HPTN 067/ADAPT. AIDS Behav. 2020;24(7):2178–2187. doi: 10.1007/s10461-020-02783-8
    1. Velloza J, Khoza N, Scorgie F, Chitukuta M, Mutero P, Mutiti K, et al.. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. J Int AIDS Soc. 2020;23(3):e25463. doi: 10.1002/jia2.25463
    1. van der Straten A, Stadler J, Luecke E, Laborde N, Hartmann M, Montgomery ET, VOICE-C Study Team. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. J Int AIDS Soc. 2014;17(3Suppl 2):19146. doi: 10.7448/IAS.17.3.19146
    1. Celum CL, Gill K, Morton JF, Stein G, Myers L, Thomas KK, et al.. Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial. J Int AIDS Soc. 2020;23(11):e25636. doi: 10.1002/jia2.25636
    1. Celum C, Mgodi N, Bekker LG, Hosek S, Donnell D, Anderson PL, et al.. PrEP adherence and effect of drug level feedback among young African women in HPTN 082. Abstract #TUAC0301. Oral presentation at the International AIDS Society Conference (IAS); July 21–24, 2019; Mexico City, Mexico.
    1. Delaney-Moretlwe S, Chersich M, Harvey S, Stangl A, Baron D, Columbini M, et al.. Empowerment clubs did not increase PrEP continuation among adolescent girls and young women in South Africa and Tanzania—results from the EMPOWER randomised trial. Abstract #13449. Oral presentation at the AIDS 2018 Conference; July 23–27, 2018; Amsterdam, Netherlands. doi: 10.3389/fmicb.2018.00409
    1. Irungu E, Khoza N, Velloza J. Multi-level interventions to promote oral pre-exposure prophylaxis use among adolescent girls and young women: a review of recent research. Curr HIV/AIDS Reports. 2021;1–10; doi: 10.1007/s11904-021-00576-9
    1. Macdonald V, Verster A, Baggaley R. A call for differentiated approaches to delivering HIV services to key populations. J Int AIDS Soc. 2017;20(Suppl 4):21658. doi: 10.7448/IAS.20.5.21658
    1. Haberer JE, Sabin L, Amico KR, Orrell C, Galarraga O, Tsai AC, et al.. Improving antiretroviral therapy adherence in resource-limited settings at scale: a discussion of interventions and recommendations. J Int AIDS Soc. 2017;20(1):21371. doi: 10.7448/IAS.20.1.21371
    1. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al.. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–829. doi: 10.1016/S1473-3099(14)70847-3
    1. Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C, et al.. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother. 2018;62(1):e01710–e01717. doi: 10.1128/AAC.01710-17
    1. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al.. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125. doi: 10.1126/scitranslmed.3004006
    1. Lei H, Nahum-Shani I, Lynch K, Oslin D, Murphy SA. A “SMART” design for building individualized treatment sequences. Annu Rev Clin Psychol. 2012;8:21–48. doi: 10.1146/annurev-clinpsy-032511-143152
    1. Levy R, Mathai M, Chatterjee P, Ongeri L, Njuguna S, Onyango D, et al.. Implementation research for public sector mental health care scale-up (SMART-DAPPER): a sequential multiple, assignment randomized trial (SMART) of non-specialist-delivered psychotherapy and/or medication for major depressive disorder and posttraumatic stress disorder (DAPPER) integrated with outpatient care clinics at a county hospital in Kenya. BMC Psychiatry. 2019;19(1):424. doi: 10.1186/s12888-019-2395-x
    1. Murphy SA. An experimental design for the development of adaptive treatment strategies. Stat Med. 2005;24(10):1455–1481. doi: 10.1002/sim.2022
    1. Shrout PE, Keyes KM, Ornstein K. Statistical Methodology for a SMART Design in the Development of Adaptive Treatment Strategies. In: Causality and Psychopathology: Finding the Determinants of Disorders and Their Cures. Oxford University Press; 2011:179–205.
    1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497. doi: 10.1056/NEJMra050100
    1. Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, et al.. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010;376(9755):1838–1845. doi: 10.1016/S0140-6736(10)61997-6
    1. Finitsis DJ, Pellowski JA, Johnson BT. Text message intervention designs to promote adherence to antiretroviral therapy (ART): a meta-analysis of randomized controlled trials. PloS One. 2014;9(2):e88166. doi: 10.1371/journal.pone.0088166
    1. Simoni JM, Huh D, Frick PA, Pearson CR, Andrasik MP, Dunbar PJ, et al.. Peer support and pager messaging to promote antiretroviral modifying therapy in Seattle: a randomized controlled trial. J Acquir Immune Defic Syndr. 2009;52(4):465–473. doi: 10.1097/qai.0b013e3181b9300c
    1. Young SD, Holloway I, Jaganath D, Rice E, Westmoreland D, Coates T. Project HOPE: online social network changes in an HIV prevention randomized controlled trial for African American and Latino men who have sex with men. Am J Public Health. 2014;104(9):1707–1712. doi: 10.2105/AJPH.2014.301992
    1. Horvath KJ, Oakes JM, Rosser BRS, Danilenko G, Vezina H, Amico KR, et al.. Feasibility, acceptability and preliminary efficacy of an online peer-to-peer social support ART adherence intervention. AIDS Behav. 2013;17(6):2031–2044. doi: 10.1007/s10461-013-0469-1
    1. Deering KN, Shannon K, Sinclair H, Parsad D, Gilbert E, Tyndall MW. Piloting a peer-driven intervention model to increase access and adherence to antiretroviral therapy and HIV care among street-entrenched HIV-positive women in Vancouver. AIDS Patient Care STDs. 2009;23(8):603–609. doi: 10.1089/apc.2009.0022
    1. Spiegel HML, Futterman DC. Adolescents and HIV: prevention and clinical care. Curr HIV/AIDS Rep. 2009;6(2):100–107. doi: 10.1007/s11904-009-0015-y
    1. Fisher EB, Boothroyd RI, Coufal MM, Baumann LC, Mbanya JC, Rotheram-Borus MJ, et al.. Peer support for self-management of diabetes improved outcomes in international settings. Health Aff. 2012;31(1):130–139. doi: 10.1377/hlthaff.2011.0914
    1. Baron D, Scorgie F, Ramskin L, Khoza N, Schutzman J, Stangle A, et al.. “You talk about problems until you feel free”: South African adolescent girls’ and young women’s narratives on the value of HIV prevention peer support clubs. BMC Public Health. 2020;20(1):1016. doi: 10.1186/s12889-020-09115-4
    1. Moore JR, Donnell DJ, Boily M-C, Mitchell KM, Delany-Moretlwe S, Bekker LG, et al.. Model-based predictions of HIV incidence among African women using HIV risk behaviors and community-level data on male HIV prevalence and viral suppression. J Acquir Immune Defic Syndr. 2020;85(4):423–429. doi: 10.1097/QAI.0000000000002481
    1. Mavhu W, Willis N, Mufuka J, Bernays S, Tshuma M, Mangenah C, et al.. Effect of a differentiated service delivery model on virological failure in adolescents with HIV in Zimbabwe (Zvandiri): a cluster-randomised controlled trial. Lancet Glob Health. 2020;8(2):e264–e275. doi: 10.1016/S2214-109X(19)30526-1
    1. Nachega JB, Sam-Agudu NA, Mofenson LM, Schechter M, Mellors JW. Achieving viral suppression in 90% of people living with Human Immunodeficiency Virus on antiretroviral therapy in low- and middle-income countries: progress, challenges, and opportunities. Clin Infect Dis. 2018;66(10):1487–1491 doi: 10.1093/cid/ciy008
    1. UNICEF. Improving the quality of pre-exposure prophylaxis implementation for adolescent girls and young women in Eastern and Southern Africa. UNICEF & WHO; 2021. Accessed December 21, 2021. Available at: .

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する